US 12,076,330 B2
Inhibition of lipofuscin aggregation by molecular tweezers
Gal Bitan, Los Angeles, CA (US); Alessandro Fraldi, Rome (IT); Alberto Auricchio, Rome (IT); and Antonio Monaco, Rome (IT)
Assigned to The Regents of the University of California, Oakland, CA (US); and FONDAZIONE TELETHON ETS, Rome (IT)
Appl. No. 17/050,401
Filed by The Regents of the University of California, Oakland, CA (US); and FONDAZIONE TELETHON ETS, Rome (IT)
PCT Filed Apr. 25, 2019, PCT No. PCT/US2019/029221
§ 371(c)(1), (2) Date Oct. 23, 2020,
PCT Pub. No. WO2020/036656, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/663,948, filed on Apr. 27, 2018.
Prior Publication US 2021/0069217 A1, Mar. 11, 2021
Int. Cl. A61K 31/6615 (2006.01)
CPC A61K 31/6615 (2013.01) 4 Claims
 
1. A method of treating a lipofuscin-related disorder in a mammal, said method comprising:
administering to said mammal an effective amount of a molecular tweezers that is capable of inhibiting the accumulation of lipofuscin aggregates;
wherein said lipofuscin-related disorder is Stargardt disease or a neuronal ceroid lipofuscinosis (NCL); and
wherein said molecular tweezers is selected from the group consisting of:

OG Complex Work Unit Chemistry